Fundraising Fox
Meadowhawk Biolabs
Marlborough, US · Founded 2021 · Delaware corporation · 1 known investors
Find your way into Meadowhawk Biolabs
Sign up to see every warm intro you have to Meadowhawk Biolabs
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Meadowhawk Biolabs team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Meadowhawk Biolabs is a contract research organization providing non-GLP bioanalytical and in vivo services—including LCMS bioanalysis, immunoanalysis, molecular analysis, and rodent pharmacology—for early-stage drug development programs. It serves pharmaceutical and biotech clients across drug modalities, operating out of Boston and San Francisco life science hubs.
Founders & leadership
PG
Peter GlickChairman & Co-FounderPeter Glick is an executive and entrepreneur with experience leading multiple life sciences and renewable energy companies through profitable growth; he previously worked in private equity and strategy consulting.
JJ
James JerseyExecutive
JS
Jessica SullivanVP Finance & AdministrationJessica Sullivan is an executive officer at Meadowhawk Biolabs with financial leadership experience across venture-backed and public companies in biotech, pharma CRO, and medical device sectors, including roles spanning startup phases through company sales and transitions to public markets. She has implemented multiple enterprise resource planning systems including PeopleSoft, Microsoft Dynamics, NetSuite, and SAP.
GP
Glick PeterNamed on SEC filing
Board
HH
Herbert HooperBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$20.3M disclosed across 3 rounds · 2021–2024
▶$5MraisedJul 2024 · 8 investors · BiotechnologyRule 506(b)
▶$5MraisedJul 2024 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Peter GlickExecutive Officer, Director
- James JerseyExecutive Officer, Director
- Jessica SullivanExecutive Officer
- Herbert HooperDirector
- Offering amount
- $5M
- Amount sold
- $5M
- First sale
- Jul 2024
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$9.3MraisedMar 2023 · 8 investors · BiotechnologyRule 506(b)
▶$9.3MraisedMar 2023 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Glick PeterExecutive Officer, Director
- Jessica SullivanExecutive Officer
- Herbert HooperDirector
- James JerseyExecutive Officer, Director
- Offering amount
- $9.3M
- Amount sold
- $9.3M
- Minimum investment
- $250K
- First sale
- Aug 2021
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$6MraisedMar 2023 · 9 investors · BiotechnologyRule 506(b)
▶$6MraisedMar 2023 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Herbert HooperDirector
- Peter GlickExecutive Officer, Director
- James JerseyExecutive Officer, Director
- Jessica SullivanExecutive Officer
- Offering amount
- $6M
- Amount sold
- $6M
- Minimum investment
- $18.6K
- First sale
- Mar 2023
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
LabcorpLabCorp provides diagnostic testing services and clinical trial recruitment solutions that connect patient insights to drug development for healthcare providers.
IQVIAIQVIA is a healthcare data and technology company that supports life sciences organizations in research, clinical development, and commercialization of medicines and medical solutions.
Companies working in the same space as Meadowhawk Biolabs.
Frequently asked questions
- What does Meadowhawk Biolabs do?
- Meadowhawk Biolabs is a contract research organization providing non-GLP bioanalytical and in vivo services—including LCMS bioanalysis, immunoanalysis, molecular analysis, and rodent pharmacology—for early-stage drug development programs. It serves pharmaceutical and biotech clients across drug modalities, operating out of Boston and San Francisco life science hubs.
- Who are Meadowhawk Biolabs's investors?
- Meadowhawk Biolabs's investors include Ampersand.
- How much funding has Meadowhawk Biolabs raised?
- Meadowhawk Biolabs has disclosed $20.3M raised across 3 rounds.
- Where is Meadowhawk Biolabs headquartered?
- Meadowhawk Biolabs is headquartered in Marlborough, US.